Clover Health Investments (CLOV) Financials

Clover Health Investments (NASDAQ:CLOV) has shown a meaningful improvement in operating performance across the reported periods, although profitability remains relatively narrow and the company continues to carry a substantial accumulated deficit. The latest data suggests a transition from heavy losses in 2022 and 2023 toward sustained quarterly profitability in 2026.

Revenue has expanded considerably. Total revenue increased from $306.0 million in Q3 2023 and $337.0 million in Q4 2024 to $749.2 million in Q1 2026 and $743.2 million in Q2 2026. Premiums earned accounted for nearly all of the latest revenue, reaching $737.8 million in Q2 2026 compared with $469.8 million in Q2 2025. The year-over-year comparison indicates strong growth, although revenue was slightly lower sequentially in Q2.

Profitability has improved sharply. Clover reported net losses of $75.5 million in Q3 2022, $41.5 million in Q3 2023 and $49.3 million in Q4 2025. By contrast, net income reached $27.3 million in Q1 2026 and $28.0 million in Q2 2026. The latest two quarters also produced basic and diluted earnings per share of $0.05, marking a substantial change from the losses reported in earlier periods.

Operating cash flow has also turned positive, but it remains volatile. Cash flow from operating activities was $107.9 million in Q1 2026 and $25.2 million in Q2 2026, compared with just $5.4 million in Q2 2025 and negative cash flow of $68.2 million in Q4 2025. The second-quarter result was supported by net income and noncash adjustments, while changes in operating assets and liabilities reduced cash flow by $12.0 million.

The balance sheet appears more streamlined than it was in 2022. Total assets declined from $1.56 billion in Q3 2022 to $720.3 million in Q2 2026, while total liabilities fell from $1.17 billion to $344.1 million over the same comparison. Cash and due from banks stood at $198.8 million in Q2 2026, supplemented by $241.7 million of trading account securities. However, cash remains below the $288.0 million reported in Q3 2024.

• Revenue growth: Q2 2026 revenue of $743.2 million was approximately 52% above Q2 2025, driven primarily by higher premiums earned.
• Recent profitability: Clover delivered two consecutive quarters of positive net income, including $28.0 million in Q2 2026.
• Improved operating cash flow: Operating cash flow remained positive in each quarter of 2026 reported here and improved substantially from late 2025.
• Balance-sheet improvement: Total liabilities and total assets are substantially lower than in 2022, reducing the company's historical balance-sheet burden.
• Positive equity position: Total common equity increased to $376.3 million in Q2 2026 from $292.5 million in Q1 2024.
• Investment portfolio provides liquidity: Trading account securities of $241.7 million add to Clover's $198.8 million of cash, although investment values can fluctuate and may not be immediately equivalent to operating cash.
• Claims costs remain manageable but important: Property and liability insurance claims were approximately 80% of premiums earned in Q2 2026, broadly similar to the recent quarterly range.
• Thin profitability: Q2 2026 pretax income was only $28.0 million on $743.2 million of revenue, leaving limited room for adverse claims, medical-cost or operating-expense trends.
• Large accumulated deficit: Retained earnings were negative $2.23 billion at the end of Q2 2026, reflecting substantial historical losses.
• Share dilution: Weighted average basic shares increased from 487.5 million in Q1 2024 to 524.2 million in Q2 2026, while diluted shares reached 545.4 million in the latest quarter.

Overall, the financial statements point to a company that has made significant progress in revenue growth, earnings and cash generation. The key question for investors is whether Clover can maintain positive earnings while keeping claims costs near current levels. The positive trend is encouraging, but the sizable accumulated deficit, volatile cash flow and rising share count remain important risks.